AMARIN PHARMA Revenue and Competitors

Bedminster, NJ USA

Location

N/A

Total Funding

Pharma

Industry

Employee Data

    00

AMARIN PHARMA's People

NameTitleEmail/Phone
1
SVP, Commercial Supply Chain & Mfg. Ops.Reveal Email/Phone
2
Sr. Director, MarketingReveal Email/Phone
3
Senior Director, Clinical DevelopmentReveal Email/Phone
4
Sr. Director, Managed Care Contracting at Amarin Pharma IncReveal Email/Phone
5
Area Sales Director (Gulf Coast)Reveal Email/Phone
6
Director, National AccountsReveal Email/Phone
7
Senior Director Regulatory AffairsReveal Email/Phone
8
Senior Director, Global Information Technology & SecurityReveal Email/Phone
9
Senior Manager, Clinical DevelopmentReveal Email/Phone
10
Regional Business ManagerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$6.6M3332%N/AN/A
#2
$38M1896%N/AN/A
#3
$6.6M3322%N/AN/A
#4
$4180M152421%$550MN/A
#5
$17.5M8750%N/AN/A
#6
$6.7M125-37%$199.6MN/A
#7
$10.9M5415%N/AN/A
#8
$15.3M7633%N/AN/A
#9
$128.6M64016%N/AN/A
#10
$18.7M9321%N/AN/A
Add Company

What Is AMARIN PHARMA?

keywords:N/A

N/A

Total Funding

N/A

Number of Employees

N/A

Revenue (est)

N/A

Employee Growth %

N/A

Valuation

N/A

Accelerator

AMARIN PHARMA News

2022-04-20 - Class action attorneys target “ethyl esters” in fish oil products

In 2017, Amarin Pharma requested an investigation by the U.S. International Trade Commission (ITC) of what it called “synthetically produced...

2022-04-19 - Amarin: Alex Denner, Health Net, Statin Combo, And Signs Of Better Times

Get them exclusively at The Total Pharma Tracker. ... I had given up on Amarin Corporation plc (NASDAQ:AMRN) after its plunge from the...

2022-04-19 - Amarin: Alex Denner, Health Net, Statin Combo, And Signs Of Better Times

There are a number of interesting developments at Amarin. Read how these may enable Amarin to regain ground it lost due to an unconscionable...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$0M2-50%$55M
#2
$0.4M30%N/A
#3
$0.2M30%N/A
#4
$0.9M1025%N/A
#5
$1M11-8%N/A